<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112341</url>
  </required_header>
  <id_info>
    <org_study_id>soh-Med-21-10-17</org_study_id>
    <nct_id>NCT05112341</nct_id>
  </id_info>
  <brief_title>Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer</brief_title>
  <official_title>Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study aiming for compairing results of hypofractionaton radiotherapy treatment in patient&#xD;
      with early breast cancer between two arms the first arm recieving five fractions and the&#xD;
      other arm recieving fifteen fraction&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1-disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>the time free from disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2- overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>the period time from treatment till death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3- toxicity from treatment</measure>
    <time_frame>2 years</time_frame>
    <description>side effects from treatment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Study on Breast Cancer Patients</condition>
  <arm_group>
    <arm_group_label>group 1 standared hypofractonation</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 fast forward group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>the patient first is simulated then delineation is done</description>
    <arm_group_label>group 1 standared hypofractonation</arm_group_label>
    <arm_group_label>group 2 fast forward group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the study includes patients with early breast cancer recieving adjuvant radiotherapy in&#xD;
        hypofractionation pattern the first arm recieving 15 fraction and the seconed arm recieving&#xD;
        five fractions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age group ( 18-80) years&#xD;
&#xD;
          -  breast conservation surgery&#xD;
&#xD;
          -  Stages (pT1-3, pN0-1, M0) breast cancer.&#xD;
&#xD;
          -  Any histological type of invasive breast cancer.&#xD;
&#xD;
          -  All grades of breast cancer (I,II,III)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage (III or IV) breast cancer.&#xD;
&#xD;
          -  Metastatic breast cancer (MBC)&#xD;
&#xD;
          -  Recurrent breast cancer.&#xD;
&#xD;
          -  Patients' co-morbidities that contraindicate radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>heba a abdelal, assistant lecturer</last_name>
    <phone>01062162612</phone>
    <phone_ext>002</phone_ext>
    <email>hebaelsagheer@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohamed s gaber, professor</last_name>
    <phone>01025876769</phone>
    <phone_ext>002</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama R ElSherif, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. Epub 2014 Sep 21.</citation>
    <PMID>25328522</PMID>
  </reference>
  <reference>
    <citation>Mascaro A, Farina M, Gigli R, Vitelli CE, Fortunato L. Recent advances in the surgical care of breast cancer patients. World J Surg Oncol. 2010 Jan 20;8:5. doi: 10.1186/1477-7819-8-5. Review.</citation>
    <PMID>20089167</PMID>
  </reference>
  <reference>
    <citation>Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Th√ºrlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.</citation>
    <PMID>25939896</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Heba Ali Elsagheer</investigator_full_name>
    <investigator_title>assistant lecturer of oncolgy. sohag university hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>adjuvant whole breast irradiation in five fractions versus fifteen fraction in early breast cancer</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>2 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

